Biotheus – Talk Bio

Actionable Insights Powered by AI

BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody

5 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, BioNTech, Biotheus, BNT327/PM8002, Cancer Therapeutic Procedure, Neoplasms, PD-L1, Vascular Endothelial Growth Factor A

BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition

BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance

5 months ago talkbio0Tagged BioNTech, Biotheus, bispecific, Drug Industry, Immunotherapy for cancer, Keytruda, PD-L1xVEGF-A

BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry